Manufacturer of Controlled Substances; Notice of Application, 75498 [2010-30358]

Download as PDF 75498 Federal Register / Vol. 75, No. 232 / Friday, December 3, 2010 / Notices letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of 4-Anilino-NPhenethyl-4-Piperidine (ANPP) (8333), a basic class of controlled substance listed in schedule II. The company plans to use this controlled substance in the manufacture of another controlled substance. Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than February 1, 2011. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. eventually cease and Agilent Technologies will take over all of Varian Inc.’s activities with regard to controlled substances, requiring possession of a DEA registration as a bulk manufacturer issued to Agilent Technologies. Presently, Agilent Technologies’ activities with regard to controlled substances will be exactly the same as performed by Varian, Inc. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than February 1, 2011. Dated: November 18, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2010–30360 Filed 12–2–10; 8:45 am] BILLING CODE 4410–09–P the public interest at this time. DEA has investigated Boehringer Ingelheim Chemicals, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: November 19, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2010–30352 Filed 12–2–10; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Mine Safety and Health Administration [FR Doc. 2010–30358 Filed 12–2–10; 8:45 am] BILLING CODE 4410–09–P Petitions for Modification of Existing Mandatory Safety Standards Drug Enforcement Administration DEPARTMENT OF JUSTICE AGENCY: Manufacturer of Controlled Substances; Notice of Application Drug Enforcement Administration Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 8, 2010, Agilent Technologies, 25200 Commercentre Drive, Lake Forest, California 92630–8810, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II: Manufacturer of Controlled Substances; Notice of Registration DEPARTMENT OF JUSTICE Drug Schedule mstockstill on DSKH9S0YB1PROD with NOTICES Phencyclidine (7471) .................... 1-piperidinocyclohex- .................... anecarbonitrile (8603) .................. Benzoylecgonine (9180) ............... Drug II II II The company plans to manufacture small quantities of the listed controlled substances for use in diagnostic products. Agilent Technologies submitted this application because, effective May 14, 2010, Varian, Inc., located at 25200 Commercentre Drive, Lake Forest, California 92630–8810, became a wholly-owned subsidiary of Agilent Technologies. Varian, Inc.’s legal existence as a corporation and as a DEA registrant as a bulk manufacturer will VerDate Mar<15>2010 16:09 Dec 02, 2010 Jkt 223001 By Notice dated May 28, 2010 and published in the Federal Register on June 8, 2010, (75 FR 32506), Boehringer Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805–9372, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances: Schedule Amphetamine (1100) .................... Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ Methadone (9250) ........................ Methadone Intermediate (9254) ... II II II II II The company plans to manufacture the listed controlled substances in bulk for sale to its customers for formulation into finished pharmaceuticals. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Boehringer Ingelheim Chemicals, Inc. to manufacture the listed basic classes of controlled substances is consistent with PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 Mine Safety and Health Administration (MSHA), Labor. ACTION: Notice. Section 101(c) of the Federal Mine Safety and Health Act of 1977 and 30 CFR part 44 govern the application, processing, and disposition of petitions for modification. This notice is a summary of petitions for modification filed by the parties listed below to modify the application of existing mandatory safety standards published in Title 30 of the Code of Federal Regulations. SUMMARY: All comments on the petitions must be received by the Office of Standards, Regulations and Variances on or before January 3, 2011. ADDRESSES: You may submit your comments, identified by ‘‘docket number’’ on the subject line, by any of the following methods: 1. Electronic Mail: zzMSHAcomments@dol.gov. Include the docket number of the petition in the subject line of the message. 2. Facsimile: 1–202–693–9441. 3. Regular Mail: MSHA, Office of Standards, Regulations and Variances, 1100 Wilson Boulevard, Room 2350, Arlington, Virginia 22209–3939, Attention: Patricia W. Silvey, Director, Office of Standards, Regulations and Variances. DATES: E:\FR\FM\03DEN1.SGM 03DEN1

Agencies

[Federal Register Volume 75, Number 232 (Friday, December 3, 2010)]
[Notices]
[Page 75498]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-30358]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on July 8, 2010, Agilent 
Technologies, 25200 Commercentre Drive, Lake Forest, California 92630-
8810, made application by letter to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of the basic classes of 
controlled substances listed in schedule II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Phencyclidine (7471).......................  II
1-piperidinocyclohex-......................  II
anecarbonitrile (8603).....................
Benzoylecgonine (9180).....................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the listed 
controlled substances for use in diagnostic products.
    Agilent Technologies submitted this application because, effective 
May 14, 2010, Varian, Inc., located at 25200 Commercentre Drive, Lake 
Forest, California 92630-8810, became a wholly-owned subsidiary of 
Agilent Technologies. Varian, Inc.'s legal existence as a corporation 
and as a DEA registrant as a bulk manufacturer will eventually cease 
and Agilent Technologies will take over all of Varian Inc.'s activities 
with regard to controlled substances, requiring possession of a DEA 
registration as a bulk manufacturer issued to Agilent Technologies. 
Presently, Agilent Technologies' activities with regard to controlled 
substances will be exactly the same as performed by Varian, Inc.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR Sec.  1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than February 1, 2011.

    Dated: November 18, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2010-30358 Filed 12-2-10; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.